Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC

Awad, 2022, Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer, Cancer Cell, 40, 10.1016/j.ccell.2022.08.003 Cabrita, 2020, Author correction: tertiary lymphoid structures improve immunotherapy and survival in melanoma, Nature, 580, E1, 10.1038/s41586-020-2155-6 Corbiere, 2011, Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases, Cancer Res., 71, 1253, 10.1158/0008-5472.CAN-10-2693 Ganesan, 2017, Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer, Nat. Immunol., 18, 940, 10.1038/ni.3775 Hu, 2021, Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma, Nat Med, 27, 515, 10.1038/s41591-020-01206-4 McAuliffe, 2021, Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy, J Immunother Cancer, 9, 10.1136/jitc-2021-003218 Ott, 2017, An immunogenic personal neoantigen vaccine for patients with melanoma, Nature, 547, 217, 10.1038/nature22991 Ott, 2020, A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or Bladder cancer, Cell, 183, 347, 10.1016/j.cell.2020.08.053 Sahin, 2017, Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer, Nature, 547, 222, 10.1038/nature23003 Ulloa-Montoya, 2013, Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy, J. Clin. Oncol., 31, 2388, 10.1200/JCO.2012.44.3762